바이오시밀러 시장(제품별 : 재조합 당화 단백질, 재조합 비당화 단백질, 재조합 펩티드) : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2022-2031년)

The report provides revenue of the global biosimilars market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global biosimilars market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the biosimilars market.

The report delves into the competitive landscape of the global biosimilars market. Key players operating in the global biosimilars market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global biosimilars market profiled in this report.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Acronyms

3. Research Methodology

4. Executive Summary: Global Biosimilars Market

5. Market Overview

• 5.1. Definition
• 5.2. Market Indicators
• 5.3. Market Dynamics
  • 5.3.1. Drivers
  • 5.3.2. Restraints
  • 5.3.3. Opportunities

6. Market Outlook

• 6.1. Global Biosimilars Market Analysis and Forecast, 2017-2031
• 6.2. Global Biosimilars Market Outlook
• 6.3. Entry Barriers to Biosimilars Market
• 6.4. Factors Driving the Adoption of Biosimilars
• 6.5. Pipeline Analysis
• 6.6. Regulatory Scenario Assessment
• 6.7. Key Industry Developments

7. Global Biosimilars Market Analysis and Forecast, by Product

• 7.1. Introduction
• 7.2. Biosimilars Market Value Forecast, by Product, 2017-2031
  • 7.2.1. Recombinant Glycosylated Proteins
    • 7.2.1.1. Monoclonal Antibodies
    • 7.2.1.2. Erythropoietin
    • 7.2.1.3. Others
  • 7.2.2. Recombinant Non-glycosylated Proteins
    • 7.2.2.1. Insulin
    • 7.2.2.2. Granulocyte Colony Stimulating Factor
    • 7.2.2.3. Recombinant Human Growth Factor
    • 7.2.2.4. Interferons
  • 7.2.3. Recombinant Peptides
• 7.3. Market Attractiveness Analysis, by Product

8. Global Biosimilars Market Analysis and Forecast, by Indication

• 8.1. Introduction
• 8.2. Biosimilars Market Value Forecast, by Indication, 2017-2031
  • 8.2.1. Chronic Diseases
  • 8.2.2. Oncology
  • 8.2.3. Autoimmune Diseases
  • 8.2.4. Infectious Diseases
  • 8.2.5. Blood Disorders
  • 8.2.6. Growth Hormone Deficiency
  • 8.2.7. Others
• 8.3. Market Attractiveness Analysis, by Material

9. Global Biosimilars Market Analysis and Forecast, by Region

• 9.1. Regional Outlook
• 9.2. Global Scenario
• 9.3. Introduction
• 9.4. Biosimilars Market Value Forecast, by Region
  • 9.4.1. North America
  • 9.4.2. Europe
  • 9.4.3. Asia Pacific
  • 9.4.4. Latin America
  • 9.4.5. Middle East & Africa
• 9.5. Market Attractiveness Analysis, by Region

10. North America Biosimilars Market Analysis and Forecast

• 10.1. Key Findings
• 10.2. North America Biosimilars Market Value Forecast, by Product, 2017-2031
  • 10.2.1. Recombinant Glycosylated Proteins
    • 10.2.1.1. Monoclonal Antibodies
    • 10.2.1.2. Erythropoietin
    • 10.2.1.3. Others
  • 10.2.2. Recombinant Non-glycosylated Proteins
    • 10.2.2.1. Insulin
    • 10.2.2.2. Granulocyte Colony Stimulating Factor
    • 10.2.2.3. Recombinant Human Growth Factor
    • 10.2.2.4. Interferons
  • 10.2.3. Recombinant Peptides
• 10.3. North America Biosimilars Market Value Forecast, by Indication, 2017-2031
  • 10.3.1. Chronic Diseases
  • 10.3.2. Oncology
  • 10.3.3. Autoimmune Diseases
  • 10.3.4. Infectious Diseases
  • 10.3.5. Blood Disorders
  • 10.3.6. Growth Hormone Deficiency
  • 10.3.7. Others
• 10.4. North America Biosimilars Market Value Forecast, by Country, 2017-2031
  • 10.4.1. U.S.
  • 10.4.2. Canada
• 10.5. North America Biosimilars Market Attractiveness Analysis
  • 10.5.1. By Product
  • 10.5.2. By Indication
  • 10.5.3. By Country

11. Europe Biosimilars Market Analysis and Forecast

• 11.1. Key Findings
• 11.2. Europe Biosimilars Market Value Forecast, by Product, 2017-2031
  • 11.2.1. Recombinant Glycosylated Proteins
    • 11.2.1.1. Monoclonal Antibodies
    • 11.2.1.2. Erythropoietin
    • 11.2.1.3. Others
  • 11.2.2. Recombinant Non-glycosylated Proteins
    • 11.2.2.1. Insulin
    • 11.2.2.2. Granulocyte Colony Stimulating Factor
    • 11.2.2.3. Recombinant Human Growth Factor
    • 11.2.2.4. Interferons
  • 11.2.3. Recombinant Peptides
• 11.3. Europe Biosimilars Market Value Forecast, by Indication, 2017-2031
  • 11.3.1. Chronic Diseases
  • 11.3.2. Oncology
  • 11.3.3. Autoimmune Diseases
  • 11.3.4. Infectious Diseases
  • 11.3.5. Blood Disorders
  • 11.3.6. Growth Hormone Deficiency
  • 11.3.7. Others
• 11.4. Europe Biosimilars Market Value Forecast, by Country/Sub-region, 2017-2031
  • 11.4.1. U.K.
  • 11.4.2. Germany
  • 11.4.3. France
  • 11.4.4. Italy
  • 11.4.5. Spain
  • 11.4.6. Rest of Europe
• 11.5. Europe Biosimilars Market Attractiveness Analysis
  • 11.5.1. By Product
  • 11.5.2. By Indication
  • 11.5.3. By Country/Sub-region

12. Asia Pacific Biosimilars Market Analysis and Forecast

• 12.1. Key Findings
• 12.2. Asia Pacific Biosimilars Market Value Forecast, by Product, 2017-2031
  • 12.2.1. Recombinant Glycosylated Proteins
    • 12.2.1.1. Monoclonal Antibodies
    • 12.2.1.2. Erythropoietin
    • 12.2.1.3. Others
  • 12.2.2. Recombinant Non-glycosylated Proteins
    • 12.2.2.1. Insulin
    • 12.2.2.2. Granulocyte Colony Stimulating Factor
    • 12.2.2.3. Recombinant Human Growth Factor
    • 12.2.2.4. Interferons
  • 12.2.3. Recombinant Peptides
• 12.3. Asia Pacific Biosimilars Market Value Forecast, by Indication, 2017-2031
  • 12.3.1. Chronic Diseases
  • 12.3.2. Oncology
  • 12.3.3. Autoimmune Diseases
  • 12.3.4. Infectious Diseases
  • 12.3.5. Blood Disorders
  • 12.3.6. Growth Hormone Deficiency
  • 12.3.7. Others
• 12.4. Asia Pacific Biosimilars Market Value Forecast, by Country/Sub-region, 2017-2031
  • 12.4.1. China
  • 12.4.2. India
  • 12.4.3. Japan
  • 12.4.4. Australia & New Zealand
  • 12.4.5. Rest of Asia Pacific
• 12.5. Asia Pacific Biosimilars Market Attractiveness Analysis
  • 12.5.1. By Product
  • 12.5.2. By Indication
  • 12.5.3. By Country/Sub-region

13. Latin America Biosimilars Market Analysis and Forecast

• 13.1. Key Findings
• 13.2. Latin America Biosimilars Market Value Forecast, by Product, 2017-2031
  • 13.2.1. Recombinant Glycosylated Proteins
    • 13.2.1.1. Monoclonal Antibodies
    • 13.2.1.2. Erythropoietin
    • 13.2.1.3. Others
  • 13.2.2. Recombinant Non-glycosylated Proteins
    • 13.2.2.1. Insulin
    • 13.2.2.2. Granulocyte Colony Stimulating Factor
    • 13.2.2.3. Recombinant Human Growth Factor
    • 13.2.2.4. Interferons
  • 13.2.3. Recombinant Peptides
• 13.3. Latin America Biosimilars Market Value Forecast, by Indication, 2017-2031
  • 13.3.1. Chronic Diseases
  • 13.3.2. Oncology
  • 13.3.3. Autoimmune Diseases
  • 13.3.4. Infectious Diseases
  • 13.3.5. Blood Disorders
  • 13.3.6. Growth Hormone Deficiency
  • 13.3.7. Others
• 13.4. Latin America Biosimilars Market Value Forecast, by Country/Sub-region, 2017-2031
  • 13.4.1. Brazil
  • 13.4.2. Mexico
  • 13.4.3. Rest of Latin America
• 13.5. Latin America Biosimilars Market Attractiveness Analysis
  • 13.5.1. By Product
  • 13.5.2. By Indication
  • 13.5.3. By Country/Sub-region

14. Middle East & Africa Biosimilars Market Analysis and Forecast

• 14.1. Key Findings
• 14.2. Middle East & Africa Biosimilars Market Value Forecast, by Product, 2017-2031
  • 14.2.1. Recombinant Glycosylated Proteins
    • 14.2.1.1. Monoclonal Antibodies
    • 14.2.1.2. Erythropoietin
    • 14.2.1.3. Others
  • 14.2.2. Recombinant Non-glycosylated Proteins
    • 14.2.2.1. Insulin
    • 14.2.2.2. Granulocyte Colony Stimulating Factor
    • 14.2.2.3. Recombinant Human Growth Factor
    • 14.2.2.4. Interferons
  • 14.2.3. Recombinant Peptides
• 14.3. Middle East & Africa Biosimilars Market Value Forecast, by Indication, 2017-2031
  • 14.3.1. Chronic Diseases
  • 14.3.2. Oncology
  • 14.3.3. Autoimmune Diseases
  • 14.3.4. Infectious Diseases
  • 14.3.5. Blood Disorders
  • 14.3.6. Growth Hormone Deficiency
  • 14.3.7. Others
• 14.4. Middle East & Africa Biosimilars Market Value Forecast, by Country/Sub-region, 2017-2031
  • 14.4.1. GCC Countries
  • 14.4.2. South Africa
  • 14.4.3. Rest of Middle East & Africa
• 14.5. Middle East & Africa Biosimilars Market Attractiveness Analysis
  • 14.5.1. By Product
  • 14.5.2. By Indication
  • 14.5.3. By Country/Sub-region

15. Competition Landscape

• 15.1. Competition Matrix
• 15.2. Market Share Analysis, by Company, 2021
• 15.3. Company Profiles
  • 15.3.1. Pfizer, Inc.
    • 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.1.2. Financial Overview
    • 15.3.1.3. Product Portfolio
    • 15.3.1.4. Strategic Overview
    • 15.3.1.5. SWOT Analysis
  • 15.3.2. Intas Pharmaceuticals Ltd.
    • 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.2.2. Financial Overview
    • 15.3.2.3. Product Portfolio
    • 15.3.2.4. Strategic Overview
    • 15.3.2.5. SWOT Analysis
  • 15.3.3. Biocon
    • 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.3.2. Financial Overview
    • 15.3.3.3. Product Portfolio
    • 15.3.3.4. Strategic Overview
    • 15.3.3.5. SWOT Analysis
  • 15.3.4. Dr. Reddy's Laboratories Ltd.
    • 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.4.2. Financial Overview
    • 15.3.4.3. Product Portfolio
    • 15.3.4.4. Strategic Overview
    • 15.3.4.5. SWOT Analysis
  • 15.3.5. Teva Pharmaceutical Industries Ltd.
    • 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.5.2. Financial Overview
    • 15.3.5.3. Product Portfolio
    • 15.3.5.4. Strategic Overview
    • 15.3.5.5. SWOT Analysis
  • 15.3.6. Sandoz International GmbH (A Novartis Division)
    • 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.6.2. Financial Overview
    • 15.3.6.3. Product Portfolio
    • 15.3.6.4. Strategic Overview
    • 15.3.6.5. SWOT Analysis
  • 15.3.7. Celltrion, Inc.
    • 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.7.2. Financial Overview
    • 15.3.7.3. Product Portfolio
    • 15.3.7.4. Strategic Overview
    • 15.3.7.5. SWOT Analysis
  • 15.3.8. Amgen, Inc.
    • 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.8.2. Financial Overview
    • 15.3.8.3. Product Portfolio
    • 15.3.8.4. Strategic Overview
    • 15.3.8.5. SWOT Analysis
  • 15.3.9. STADA Arzneimittel AG
    • 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.9.2. Financial Overview
    • 15.3.9.3. Product Portfolio
    • 15.3.9.4. Strategic Overview
    • 15.3.9.5. SWOT Analysis
  • 15.3.10. Apotex Inc. (Apobiologix)
    • 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 15.3.10.2. Financial Overview
    • 15.3.10.3. Product Portfolio
    • 15.3.10.4. Strategic Overview
    • 15.3.10.5. SWOT Analys